Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Envafolimab plus chemoradiotherapy for locally advanced nasopharyngeal carcinoma
NCT05397769Phase 2
Key facts
- Status
- Recruiting
- Start
- Jun 2022
- Primary completion
- Jun 2026
- Countries
- 1
- Sponsor
- Sun Yat-sen University
- Modality
- Nanobodies (VHH), Monoclonal Antibodies
- Drugs
- envafolimab
- Conditions
- nasopharyngeal carcinoma (NPC)
01
Overview
Phase 2, open-label, single-arm trial of envafolimab in nasopharyngeal carcinoma (NPC), sponsored by Sun Yat-sen University. Primary endpoint: Progression-Free Survival at 3 years. Started Jun 2022; status: recruiting.
02
Design
1 arm- Study design
- Non-randomizedOpen-labelSingle group
Envafolimab group
Induction GP + Envafolimab followed by Concurrent DDP + Envafolimab + RT followed by Maintenance Envafolimab
03
Who it enrols
Patients with stage III-IVa locally advanced, non-keratinizing nasopharyngeal carcinoma who have not received prior radiation or chemotherapy.
04
Endpoints
Primary
Progression-Free Survival
Beyond the preview
Go deeper on NCT05397769.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05397769.